NCT01413191View on ClinicalTrials.gov

Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

June 30, 2014

Conditions
Ciliary Body and Choroid Melanoma, Medium/Large SizeCiliary Body and Choroid Melanoma, Small SizeIris MelanomaMetastatic Intraocular MelanomaRecurrent Intraocular MelanomaStage IV Intraocular Melanoma
Interventions
BIOLOGICAL

Cixutumumab

10 mg/kg IV infusion over 1 hour every 2 weeks with treatment cycle defined as 4 weeks

OTHER

Laboratory biomarker analysis

Correlative studies

Trial Locations (2)

19107

Thomas Jefferson University Hospital, Philadelphia

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01413191 - Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye | Biotech Hunter | Biotech Hunter